Altered thymidylate synthetase in 5-fluorodeoxyuridine-resistant Ehrlich ascites carcinoma cells.
Thymidylate synthetase from 5-fluorodeoxyuridine-resistant Ehrlich ascites carcinoma cells was purified to a state close to electrophoretical homogeneity (sp. act. = 1.3 mumoles/min/mg protein) and studied in parallel with the homogeneous preparation of the enzyme from the parental Ehrlich ascites carcinoma cells. The enzyme from the resistant cells compared to that from the parental cells showed: (i) a higher turnover number (at least 91 against 31 min-1), (ii) a higher inhibition constant (19 against 1.9 nM) for FdUMP (a tight-binding inhibitor of both enzymes), (iii) a lower activation energy at temps above 36 degrees (1.37 against 2.59 kcal/mole), and (iv) a lower inhibition constant (26 against 108 microM) for dTMP, inhibiting both enzymes competitively vs dUMP.
D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000201:enzymology*; D002460:Cell Line; D004351:Drug Resistance; D004591:Electrophoresis, Polyacrylamide Gel; D005467:Floxuridine / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D008727:Methotrexate / Q000494:pharmacology; D008780:Methyltransferases / Q000302:isolation & purification*; D008970:Molecular Weight; D013696:Temperature; D013937:Thymidine Kinase / Q000032:analysis; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors / Q000302:isolation & purification* / Q000378:metabolism
D005467:Floxuridine; D008780:Methyltransferases; D013940:Thymidylate Synthase; D013937:Thymidine Kinase; D008727:Methotrexate